Early Detection and Diagnosis
Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study†
Article first published online: 31 JAN 2008
Copyright © 2008 Wiley-Liss, Inc.
International Journal of Cancer
Volume 122, Issue 10, pages 2294–2300, 15 May 2008
How to Cite
Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R. and Soutter, W. P. (2008), Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study. Int. J. Cancer, 122: 2294–2300. doi: 10.1002/ijc.23339
Conflict of Interest: Jack Cuzick serves on the speaker's bureau for Digene Corporation and the advisory board for Roche Molecular Systems and the department has received research funding from Digene Corporation, Roche, MTM, Norchip, Genprobe and GlaxoSmithKline.
- Issue published online: 17 MAR 2008
- Article first published online: 31 JAN 2008
- Manuscript Accepted: 16 OCT 2007
- Manuscript Received: 23 MAY 2007
- European Commission (ECCCE group). Grant Number: QL-C4-2000-1238
- Cancer Research UK programme. Grant Number: MS4001
- Digene Corporation
- 5The new technologies for cervical cancer screening (NTCC) working group human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547–55., , , , , , , , , , , , et al.
- 6Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme, Chapter 42. In: FrancoE,MonsonegoJ, eds. New developments in cervical cancer screening and prevention. Oxford: Blackwell Science, 1997; 364–72., .